VeriTeQ Launches New Readers Based on Demand From Breast Implant Industry
DELRAY BEACH, Fla., Sept. 18, 2014 (GLOBE NEWSWIRE) — VeriTeQ Corporation (“VeriTeQ”) (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, announced today that it has unveiled two new readers used to identify VeriTeQ’s Q Inside Safety Technology™ within implantable medical devices: the Q Inside Reader + and the Q Inside Reader XR +. The new readers are being launched based on demand from the breast implant industry.
A photo accompanying this release is available at http://www.globenewswire.com/newsroom/prs/?pkgid=27730
The readers will identify VeriTeQ’s Q Inside Safety Technology micro-transponders used for unique medical device identification. The Q Inside Reader + is Bluetooth-enabled and comes complete with a USB lead for charging the reader’s internal rechargeable battery. The Q Inside Reader XR + is also Bluetooth-enabled and has an extended read-range.
VeriTeQ’s FDA cleared Q Inside Safety Technology™ acts as an electronic serial number in breast implants and other implantable and reusable medical devices to provide physicians and patients access to secure online databases to retrieve device-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the medical device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.
“Feedback from our customers and technology innovation has always been a vital part of our business, so we felt it was necessary to evolve our product offerings to meet the demands of those who are critical to our growth,” said Scott R. Silverman, VeriTeQ’s Chairman and Chief Executive Officer. “The new Q Inside readers are compact and easy-to-use, with a look and feel that better represents the aesthetic of the industry we serve.”
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world’s first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ’s dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Statements in this press release about our future expectations, including the likelihood that Q Inside Safety Technology may also provide an extra level of protection to the patient in the event of a recall or other safety event; constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ‘s ability to raise capital; as well as other risks. Additional information about these and other factors may be described in VeriTeQ‘s Form 10-K, filed on April 15, 2014, and Forms 10-Q, filed on August 20, 2014, May 14, 2014, and November 14, 2013, and future filings with the Securities and Exchange Commission. The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
The photo is also available at Newscom, www.newscom.com, and via AP PhotoExpress.
Allison Tomek, 561-846-7003